Literature DB >> 10828763

Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy.

P Hovind1, L Tarnow, P B Oestergaard, H H Parving.   

Abstract

BACKGROUND: Growth factors have been suggested to play a role in the development and progression of diabetic nephropathy. Vascular endothelial growth factor (VEGF) is a potent cytokine family that induces angiogenesis and markedly increases endothelial permeability. The aim of the present study was to investigate plasma levels of VEGF in a large cohort of type 1 diabetic patients with diabetic nephropathy and in long-standing type 1 diabetic patients with persistent normoalbuminuria, and to evaluate VEGF as a predictor of nephropathy progression.
METHODS: We measured VEGF with an enzyme-linked immunosorbent assay (ELISA) technique in 199 type 1 diabetic patients with diabetic nephropathy (122 males, age 41 +/- 10 years, diabetes duration 28 +/- 8 years), glomerular filtration rate (GFR) (median [range]) 75 [10-143] mL/min/1.73 m2, and in 188 long-standing type 1 diabetic patients with persistent normoalbuminuria (115 males, age 43 +/- 10 years, diabetes duration 27 +/- 9 years). One hundred fifty-five of the proteinuric patients were followed for at least 3 years after baseline examination with yearly GFR measurements.
RESULTS: Plasma levels of VEGF were significantly increased in patients with nephropathy as compared to the normoalbuminuric group; (median [range]): 45.7 [22.0-410] versus 27.1 [22.0-355] ng/L, respectively, P < 0.001. This difference was ascribed to elevated VEGF levels in nephropathic men: 51.8 [22.0-410] versus 22.0 [22.0-308] ng/L, P < 0. 001. No differences were found between women with and without nephropathy: 37.8 [22.0-325] versus 36.6 [22.0-335] ng/L, NS. In proteinuric patients with GFR above and below the median value, there was no difference in the level of VEGF, NS. Plasma VEGF was below the detection limit (22.0 ng/L) in 60 patients with nephropathy and 93 patients with normoalbuminuria, P < 0.001. The mean rate of GFR decline was 3.5 (SE: 0.4) mL/min/year, and the following baseline variables acted as predictors of progression: albuminuria, mean arterial blood pressure and male gender. Hemoglobin A1c and plasma VEGF did not act as predictors. No significant differences between patients with and without proliferative retinopathy were detected.
CONCLUSIONS: Our data suggest that VEGF is elevated early in the course of diabetic nephropathy in men with type 1 diabetes mellitus. Baseline albuminuria, arterial blood pressure and male gender was predictors of diabetic nephropathy progression, while plasma VEGF and Hemoglobin A1c did not contribute. The importance of VEGF in the initiation of diabetic nephropathy remains to be established.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828763

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  28 in total

1.  Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes.

Authors:  Claudia Bertuccio; Delma Veron; Pardeep K Aggarwal; Lawrence Holzman; Alda Tufro
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

3.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

4.  Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.

Authors:  D Veron; C A Bertuccio; A Marlier; K Reidy; A M Garcia; J Jimenez; H Velazquez; M Kashgarian; G W Moeckel; A Tufro
Journal:  Diabetologia       Date:  2011-02-12       Impact factor: 10.122

5.  Elevated plasma levels of endostatin are associated with chronic kidney disease.

Authors:  Jing Chen; L Lee Hamm; Myra A Kleinpeter; Fred Husserl; Islam Enver Khan; Chung-Shiuan Chen; Yanxi Liu; Katherine T Mills; Chuan He; Nader Rifai; Eric E Simon; Jiang He
Journal:  Am J Nephrol       Date:  2012-03-27       Impact factor: 3.754

Review 6.  Vascular endothelial growth factor and diabetic nephropathy.

Authors:  Sheldon Chen; Fuad N Ziyadeh
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

7.  Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.

Authors:  Samy Hakroush; Marcus J Moeller; Franziska Theilig; Brigitte Kaissling; Tjeerd P Sijmonsma; Manfred Jugold; Ann L Akeson; Milena Traykova-Brauch; Hiltraud Hosser; Brunhilde Hähnel; Hermann-Josef Gröne; Robert Koesters; Wilhelm Kriz
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

8.  Getting a notch closer to understanding diabetic kidney disease.

Authors:  Seon-Ho Ahn; Katalin Susztak
Journal:  Diabetes       Date:  2010-08       Impact factor: 9.461

Review 9.  Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease.

Authors:  Omar C Logue; Jeremy W D McGowan; Eric M George; Gene L Bidwell
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-09       Impact factor: 2.894

10.  Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat.

Authors:  Shujun Chen; Haiping Chen; Qi Liu; Qing Ma
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.